Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin.
BACKGROUND
The survival rate of patients with advanced stage primary squamous cell carcinoma of the ovary is dismal and the best treatment is unknown. We describe the response of this tumor to systemic chemotherapy employing paclitaxel and cisplatin.


METHODS
A 31-year-old white woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary squamous cell carcinoma of the ovary associated with ovarian endometriosis underwent cytoreductive surgery followed by paclitaxel and cisplatin every 4 weeks for 12 courses. The patient tolerated chemotherapy well, demonstrated a dramatic response with disappearance of hepatic metastases, and remains without evidence of disease 2 years after diagnosis.


CONCLUSIONS
Paclitaxel and cisplatin may be effective in treating primary squamous cell carcinoma of the ovary.
Eltabbakh
G H
GH
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. geltabba@aol.com
Hempling
R E
RE
Recio
F O
FO
O'Neill
C P
CP
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
D017239:Paclitaxel; D002945:Cisplatin